Skip to main content
. 2017 Jun 5;4(4):e360. doi: 10.1212/NXI.0000000000000360

Figure 1. Cladribine targets mainly lymphocytes.

Figure 1

Mean number of red blood cells and leucocytes following treatment with either placebo (n = 42–101. Typically, the lower limit of sample size was n = 63, except week on 55) or a total doses of either 3.5 mg/kg (n = 47–103. Typically, the lower limit of sample size was n = 67, except on week 55) or 5.25 mg/kg (n = 38–104. Typically, the lower limit of sample size was n = 62, except on week 55). Placebo (circle) or cladribine (CLAD) that was administered in monthly courses (inverse triangle) at 0, 5 and 48 and 52 weeks (diamond; 3.5 mg per dose) and additionally at 9 and 13 weeks (hexagon; 5.25 mg per dose). The results show the mean ± SEM of (A) red blood cells (B) platelets (C) white blood cells, (D) lymphocytes, (E) monocytes, (F) polymorphonuclear neutrophils, (G) eosinophils, or (H) basophils.